CN105287543A - Application of strynuxlines B to prepare medicines treating or preventing oral ulcer - Google Patents

Abstract

The invention relates to application of strynuxlines B to prepare medicines treating or preventing oral ulcer, and the application is disclosed for the first time. Because the framework type belongs to a brand-new framework type and the activity of strynuxlines B treating oral ulcer is strong, the technical scheme possesses prominent substantive features, and also application to treat oral ulcer obviously possesses notable progress.

Description

The application of Strynuxlines B in preparation treatment or preventing canker sore medicine

Technical field

The present invention relates to the novelty teabag of compound S trynuxlinesB, particularly relate to the application of StrynuxlinesB in preparation treatment or preventing canker sore medicine.

Background technology

Recurrent oral ulceration is modal disease in diseases of oral mucosa.The first place of prevalence office diseases of oral mucosa.Sircus (1975) investigates 1587 people, and prevalence is 20%.As can be seen here, oral ulcer patient is a very huge colony.The cause of disease of recurrent oral ulceration is complicated, still indefinite so far, may be relevant with the factor such as the endocrine regulation of viral infection, bacteriological infection and body, immune dysfunction.The primary treatment measure of oral ulcer comprises topical therapeutic and whole body therapeutic, and because topical therapeutic toxic and side effects is lower, the people therefore obtaining people can.Although the buccal tablets that the local that occurs in recent years uses carries, easy to use, mouthfeel and compliance better, as lysozyme buccal tablet, watermelon crystal buccal tablet, cydiodine etc., these medicines emphasize particularly on different fields in sterilization, antiinflammatory, pain relieving etc.

The compound S trynuxlinesB that the present invention relates to is one and delivers (YanhuiFu in 2012, etal., StrynuxlinesAandB, AlkaloidswithanUnprecedentedCarbonSkeletonfromStrychnosn ux-vomica.J.Nat.Prod.2012, 75, noval chemical compound 1987-1990.), this compound has brand-new framework types, only can breed (YanhuiFu by inhibition tumor cell, etal., StrynuxlinesAandB, AlkaloidswithanUnprecedentedCarbonSkeletonfromStrychnosn ux-vomica.J.Nat.Prod.2012, 75, 1987-1990., the purposes of the StrynuxlinesB that the present invention relates in preparation treatment or preventing canker sore medicine belongs to first public.

Summary of the invention

The object of the invention is to not find that it has the present situation of the report for the treatment of or preventing canker sore according in existing StrynuxlinesB research, provide the application of StrynuxlinesB in preparation treatment or preventing canker sore medicine.

Described compound S trynuxlinesB structure is as shown in formula I:

Formula I

The purposes of the StrynuxlinesB that the present invention relates in preparation treatment or preventing canker sore medicine belongs to first public, because framework types belongs to brand-new framework types, and its treatment or preventing canker sore active strong, possess outstanding substantive distinguishing features, to be used for the treatment of or preventing canker sore obviously has significant progress simultaneously.

Detailed description of the invention

The preparation method of compound S trynuxlinesB involved in the present invention is see document (YanhuiFu, etal., StrynuxlinesAandB, AlkaloidswithanUnprecedentedCarbonSkeletonfromStrychnosn ux-vomica.J.Nat.Prod.2012,75,1987-1990.)

The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.

Embodiment 1: the preparation of compound S trynuxlinesB tablet involved in the present invention:

Get 5 g of compound StrynuxlinesB and add 195 grams, dextrin, mixing, Conventional compression makes 1000.

Embodiment 2: the preparation of compound S trynuxlinesB capsule involved in the present invention:

Get 5 g of compound StrynuxlinesB and add starch 195 grams, mixing, encapsulatedly makes 1000.

Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.

The experimental study of test example 1:StrynuxlinesB anti-oral ulcer

1, test objective: manufacture Oral ulcer model with phenol, gives the StrynuxlinesB of Oral ulcer model rat certain number of times every day, and whether observe StrynuxlinesB has the effect reducing ulcer.

2, test medicine and reagent

Cydiodine (Beijing Sihuan Medicine Science and Technology Co., Ltd); Phenol

Animal: Wistar rat, male, body weight 240 ~ 280g, Nanjing Medical University's Experimental Animal Center.

3, test method

Get rat 50, male, body weight 240 ~ 280g, 10% chloral hydrate anesthesia, dosage: 0.35ml/100g, after anesthesia, plastic dropper (internal diameter: the 3mm) lower end of 90% phenol cotton balls being flat on rats with left bicker is about on the cheek film at 1mm place, calcination 30min, namely sees the white infringement of this place about 3mm.Divide into groups immediately after 24 hours, often organize 10, divide 5 groups, i.e. model group (adjuvant 4 times/day, not drug containing); StrynuxlinesB high dose group (4 times/day, 0.5mg/ time); Dosage (4 times/day, 0.1mg/ time) in StrynuxlinesB; StrynuxlinesB low dose group (4 times/day, 0.02mg/ time); Positive controls: cydiodine group (4 times/day, 0.5mg/ time).StrynuxlinesB and cydiodine buccal tablet pulverize before use, administration is degree of being with flap coverage.Successive administration 5 days, after the front and each administration of administration, next day observes ulcer area size (diameter in ulcer) and ulcer healing situation (being considered as healing without macroscopic ulcer), and first administration is recorded as 1,2,3,4,5,6 day respectively to last administration.Ulcer area size t checks, and ulcer healing rate X2 checks.

4, result of the test

Ulcer area compares (table 1): StrynuxlinesB high dose group compares with model group, within the 3rd day, plays off-test from administration, and corresponding every day compares significant difference; Cydiodine group compares with model group, within the 3rd day, plays off-test from administration, and corresponding every day compares significant difference; In StrynuxlinesB, dosage group compares with model group, within the 3rd day, plays off-test from administration, and corresponding every day compares significant difference; StrynuxlinesB low dose group compares with model group, within the 5th day, plays off-test from administration, and corresponding every day compares significant difference; In StrynuxlinesB, dosage group compares with cydiodine group, within the 1st day, plays off-test from administration, and corresponding every day compares significant difference.

Table 1 is on the impact of rat ulcer area

Note: compare with model group, * p<0.05, * p<0.01.

Healing rate (table 2): model group and StrynuxlinesB low dose group play off-test on the 1st day from administration, and ulcer does not heal; And StrynuxlinesB high dose group was from administration the 4th day, just there is ulcer healing, to off-test, reach 90%; Cydiodine group, from administration the 4th day, has ulcer healing, to off-test, reaches 60%; In StrynuxlinesB, dosage group was from administration the 5th day, had ulcer healing, to off-test, reached 40%.

Table 2 is on the impact of rat ulcer healing time

Note: compare with model group, * p<0.05, * p<0.01.

5, conclusion

StrynuxlinesB has the effect obviously promoting oral ulcer healing.

Claims (1)

1. The application of 1.StrynuxlinesB in treatment or preventing canker sore medicine, described compound S trynuxlinesB structure is as shown in formula I:

   Formula I.